Pharma News - Chemdiv

NICE Recommends Sanofi and Regeneron’s Libtayo for CSCC

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Sanofi and Regeneron’s Libtayo (cemiplimab) for National Health Service (NHS) use in the treatment of patients ...

United Therapeutics’ Tyvaso DPI Approved for Rare High Blood Pressure Disease

The FDA has approved United Therapeutics’ Tyvaso DPI (trepostinil) in an inhaled powder formulation for patients with pulmonary arterial hypertension, a rare type of high blood pressure dis...

UCLA Researchers Identify HIV Drug That Could Combat Memory Loss

Researchers at the University of California, Los Angeles have identified a neurological mechanism behind memory linking.

Senate Passes Legislation to Address Medication Accessibility, Affordability

Senate Majority to Advance Legislation to Make Prescription Drugs More Affordable.

Pfizer to Expand Its Largest Manufacturing Site to Increase Paxlovid Supply

Pfizer said it will expand its Kalamazoo, Mich., manufacturing facility to increase production of its COVID-19 drug Paxlovid (nirmatrelvir, ritonavir).

Lilly sets aside $2.1bn for domestic investments

Eli Lilly’s home state of Indiana is set to benefit from a massive $2.1 billion investment by the pharma group, earmarked for two brand new manufacturing facilities. ...

AbbVie adds to Vraylar data as FDA considers depression use

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression, as it waits for a decision by the FDA on the new indication. ...

Bavarian Nordic Enters First Larger Vaccine Contract with Government in Response to Monkeypox Outbreak

Bavarian Nordic A/S (OMX: BAVA) announced today the signing of a supply contract with an undisclosed country for the Company’s smallpox vaccine with the aim to ensure sufficient supply to meet th...

Pfizer and Lilly Zero in on Success in Ulcerative Colitis

Two big pharma companies are forging ahead with ulcerative colitis (UC) research after posting positive results from their respective Phase III studies.

Junshi Biosciences Oral Covid Drug Wraps Up Trials, to Seek Sales Approval

Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) announced late Monday that VV116, an oral drug developed by its JunTop Biosciences unit for the early treatment of Covid-19,...

Europe: Pause recommended for 100 generics

Approval for around 100 generics in Europe is to be suspended because a contract institute in India has worked poorly in the studies relevant to the approval of the drugs.

Pfizer Expected to Pay $290,000 to Patients in Four States in Settlement

Pfizer has agreed to pay $290,000 to patients in Colorado, Vermont, Arizona and Kansas to settle allegations over alleged misleading copay coupons for four drugs. ...

Pharma News, 2022